Ketotifen

Ketotifen is a medication classed as an antihistamine and mast cell stabilizer, used to treat and prevent allergic disorders ^[1]. Chemically it is a tricyclic compound built on a benzocycloheptathiophene framework, closely related to the migraine drug pizotifen ^[1]. Its classification between the older, sedating first-generation antihistamines and the newer second-generation agents is somewhat ambiguous, because it resembles first-generation drugs in structure yet has a long duration of action more typical of the newer class ^[1].

The drug was developed by the Swiss company Sandoz, later part of Novartis; it was patented in 1970 and came into medical use in 1976 ^[1]. An eye-drop formulation for allergic eye symptoms was approved in the United States in 1999 and later became available over the counter ^[3]. It is sold worldwide under many names, most commonly Zaditor and Zaditen ^[1].

Ketotifen is used in two main ways. As eye drops it is a well-established treatment for the itching and irritation of allergic conjunctivitis, providing relief quickly, and reviews of topical antihistamines and mast cell stabilizers place it among effective options for seasonal and perennial allergic eye disease ^[2][3]. Taken by mouth it is used as a preventive treatment for bronchial asthma and for allergic conditions including allergic rhinitis, chronic urticaria, atopic dermatitis, and food allergy; in asthma it reduces symptoms and the need for other medicines in a substantial proportion of patients, with an efficacy comparable to sodium cromoglicate, although it must be taken for weeks before its full effect appears ^[1][4]. It has also been used in the management of mast cell activation disorders ^[1].

The compound owes its effects to the combination of H1 histamine blockade and stabilization of mast cells, the same pairing that underlies its broad activity across different allergic tissues ^[1][4].

In terms of availability, the ophthalmic drops are sold over the counter in the United States, whereas oral forms such as tablets and syrups are prescription medicines in countries including Canada and much of Europe and are not marketed as an approved oral product in the United States ^[1]. The main drawbacks of oral therapy are sedation, which tends to ease after the first couple of weeks, and weight gain in a minority of users; the eye drops are generally well tolerated, with transient stinging or eye irritation being the usual complaints ^[1][3].

Ketotifen eye drops are available over the counter and are generally very safe, with occasional eye stinging or headache. The oral form is usually prescription and commonly causes drowsiness, dry mouth, weight gain and increased appetite, partly from its antihistamine and anticholinergic effects. Because the oral form is sedating, it adds to the effects of alcohol and other sedatives. It prevents symptoms rather than relieving an acute asthma attack.

Ketotifen was developed by the Swiss pharmaceutical company Sandoz and introduced in the 1970s as an antihistamine with an additional mast-cell-stabilizing action, an uncommon combination in a single molecule. Taken by mouth, it was used to help prevent the symptoms of asthma and other allergic disorders, its benefit building gradually over several weeks of regular use. Structurally related to older sedating antihistamines, it readily enters the brain, which accounts for the drowsiness that can accompany oral therapy, particularly in the first weeks.

The compound found a second and enduring role in ophthalmology as an eye-drop formulation, marketed under names such as Zaditor and Zaditen, for the rapid relief of itching in allergic conjunctivitis; low-strength versions later became available over the counter. Its dual mechanism, blocking the H1 histamine receptor while also preventing mast cells from releasing their inflammatory cargo, places it at the intersection of the antihistamines and the cromone mast-cell stabilizers. It remains a familiar and widely used anti-allergic agent.

Ketotifen is well liked for combining two useful anti-allergic actions in one molecule, and its ophthalmic form in particular has become a trusted, fast-acting remedy for the itch and redness of allergic conjunctivitis. By both blocking the H1 histamine receptor and stabilizing mast cells so they release fewer inflammatory mediators, it addresses an allergic reaction from two directions at once, which reviewers of ocular allergy therapy count among its notable strengths.

As eye drops it is convenient, widely available, and gentle enough for over-the-counter use in many markets. Taken orally for asthma and allergic disease, it offers preventive benefit, though patients should know that this effect accumulates gradually and that the oral form can cause drowsiness early in treatment because it crosses into the brain. Balanced against these modest caveats, it is a versatile and dependable option for allergic symptom control.